Literature DB >> 15278371

No effect on adenoma formation in Min mice after moderate amount of flaxseed.

S Oikarinen1, S-M Heinonen, T Nurmi, H Adlercreutz, M Mutanen.   

Abstract

BACKGROUND & AIM: The mammalian lignan enterolactone (ENL) produced from plant lignans, e. g. secoisolariciresinol diglycoside (SDG), may protect against various cancers in humans. The present work aims to evaluate the effect of flaxseed on tumour formation in multiple intestinal neoplasia (Min) mice, a model for colon tumorigenesis.
DESIGN: Male and female Min mice were fed either with a non-fibre control diet or the same diet supplemented with 0.5 % (w/w) defatted flaxseed meal. Conversion of SDG to the mammalian lignans enterodiol (END) and ENL in the gut, and plasma ENL, were measured by HPLC with coulometric electrode array detector (CEAD) and timeresolved fluoroimmunoassay, respectively. Wild-type mice were also fed with the experimental diets in order to see whether lignan metabolism is different in Min and wild-type mice.
RESULTS: The total number of adenomas or their size in the small intestine was not different in the flaxseed and control groups. The flaxseed group had a tendency for a decreased number of colon adenomas in both genders. Gender and genotype based differences were found in the intestinal ENL levels. When compared to Min females, Min males in the flaxseed group had several fold higher ENL levels in the small intestine (Min males 125 +/- 124.5 nmol/g vs. females 22.8 +/- 16.0 nmol/g, P = 0.048) and caecum (47.6 +/- 31.6 nmol/g vs. females 14.5 +/- 6.6 nmol/g, P = 0.001). Presence of adenomas in the gut influences the intestinal lignan metabolism. Min mice had less intestinal END and ENL as compared with the wild-type mice (P < 0.05). Mean plasma ENL increased 7-fold during the flaxseed feeding (7 nmol/L in control vs. 50 nmol/L in flaxseed group) but no differences between gender and genotype were found. The plasma ENL level did not correlate with adenoma number in the small intestine and colon.
CONCLUSION: The number of intestinal adenomas in the Min mouse model is not related to ENL level in plasma nor is it associated with the levels of intestinal lignans. A gender difference in ENL lignan metabolism was found in the gut but not in the plasma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278371     DOI: 10.1007/s00394-004-0521-z

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  39 in total

1.  Chemopreventive activity of crude hydroxsymatairesinol (HMR) extract in Apc(Min) mice.

Authors:  S I Oikarinen; A Pajari; M Mutanen
Journal:  Cancer Lett       Date:  2000-12-20       Impact factor: 8.679

2.  Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon.

Authors:  J E Paulsen; I L Steffensen; E M Løberg; T Husøy; E Namork; J Alexander
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Time-resolved fluoroimmunoassay for plasma enterolactone.

Authors:  H Adlercreutz; G J Wang; O Lapcík; R Hampl; K Wähälä; T Mäkelä; K Lusa; M Talme; H Mikola
Journal:  Anal Biochem       Date:  1998-12-15       Impact factor: 3.365

Review 4.  Biliary excretion and intestinal metabolism of progesterone and estrogens in man.

Authors:  H Adlercreutz; F Martin
Journal:  J Steroid Biochem       Date:  1980-02       Impact factor: 4.292

5.  Dietary supplementation with secoisolariciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice.

Authors:  D Li; J A Yee; L U Thompson; L Yan
Journal:  Cancer Lett       Date:  1999-07-19       Impact factor: 8.679

6.  Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis.

Authors:  F Grodstein; P A Newcomb; M J Stampfer
Journal:  Am J Med       Date:  1999-05       Impact factor: 4.965

7.  Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham study(1-4).

Authors:  M J de Kleijn; Y T van der Schouw; P W Wilson; H Adlercreutz; W Mazur; D E Grobbee; P F Jacques
Journal:  J Nutr       Date:  2001-06       Impact factor: 4.798

8.  Plasma enterolactone or intestinal Bifidobacterium levels do not explain adenoma formation in multiple intestinal neoplasia (Min) mice fed with two different types of rye-bran fractions.

Authors:  S Oikarinen; S Heinonen; S Karppinen; J Mättö; H Adlercreutz; K Poutanen; M Mutanen
Journal:  Br J Nutr       Date:  2003-07       Impact factor: 3.718

9.  Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet.

Authors:  H Adlercreutz; H Honjo; A Higashi; T Fotsis; E Hämäläinen; T Hasegawa; H Okada
Journal:  Am J Clin Nutr       Date:  1991-12       Impact factor: 7.045

10.  Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis.

Authors:  L U Thompson; S E Rickard; L J Orcheson; M M Seidl
Journal:  Carcinogenesis       Date:  1996-06       Impact factor: 4.944

View more
  3 in total

Review 1.  Mouse models for unraveling the importance of diet in colon cancer prevention.

Authors:  Alexandra E Tammariello; John A Milner
Journal:  J Nutr Biochem       Date:  2010-02       Impact factor: 6.048

2.  Dietary flaxseed prevents radiation-induced oxidative lung damage, inflammation and fibrosis in a mouse model of thoracic radiation injury.

Authors:  James C Lee; Ryan Krochak; Aaron Blouin; Stathis Kanterakis; Shampa Chatterjee; Evguenia Arguiri; Anil Vachani; Charalambos C Solomides; Keith A Cengel; Melpo Christofidou-Solomidou
Journal:  Cancer Biol Ther       Date:  2009-01-01       Impact factor: 4.742

3.  Radioprotective role in lung of the flaxseed lignan complex enriched in the phenolic secoisolariciresinol diglucoside (SDG).

Authors:  Melpo Christofidou-Solomidou; Sonia Tyagi; Ralph Pietrofesa; Floyd Dukes; Evguenia Arguiri; Jason Turowski; Philip A Grieshaber; Charalambos C Solomides; Keith A Cengel
Journal:  Radiat Res       Date:  2012-10-29       Impact factor: 2.841

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.